SW
RXRX icon

SteelPeak Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

SteelPeak Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-84,576
Closed -$428K – 649
2025
Q2 		$428K Buy
84,576
+14,615
+21% +$71.8K 0.02% 372
2025
Q1 		$370K Sell
69,961
-3,559
-5% -$25.9K 0.02% 386
2024
Q4 		$497K Sell
73,520
-14,754
-17% -$99.2K 0.02% 341
2024
Q3 		$582K Buy
88,274
+66,742
+310% +$478K 0.03% 290
2024
Q2 		$161K Buy
+21,532
New +$188K 0.01% 476

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SteelPeak Wealth's RXRX Position: Q3 2025 in Review

SteelPeak Wealth sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 84,576 shares — an estimated $428K sold.

SteelPeak Wealth first reported a position in RXRX in Q2 2024 and held it in 5 quarters. The position peaked at $582K in Q3 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • SteelPeak Wealth reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • SteelPeak Wealth sold 84,576 Recursion Pharmaceuticals shares in Q3 2025, an estimated $428K.
  • SteelPeak Wealth first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • SteelPeak Wealth's Recursion Pharmaceuticals position peaked at $582K in Q3 2024.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on SteelPeak Wealth's 13F filing for Q3 2025, filed 21 Oct 2025.